Management Team
Dr. Charles Phillips
Chief Medical Officer
Charles Phillips, MD, MBA is responsible for the clinical development plan and providing the overall management strategy for the project. He has worked for big pharma in both research and commercial roles holding senior management positions and has worked on both sides of the Atlantic. He has particular expertise in regulatory submission (Edoxaban), cardiovascular drugs (Fondaparinux), antibodies and reversal agents. Charles is based in the US.
Dr James C Keith Jr
Chief Executive Officer
James C. Keith Jr., D.V.M., Ph.D. has held physiology and pharmacology positions in academia as well as senior positions in biotech and pharmaceutical companies, and has consulted globally in drug discovery and development. He is an expert in models of human disease, including study design, review and analysis, scientific report preparation and manuscript preparation. Author or co-author of over 145 peer-reviewed papers and book chapters, he has contributed to the approval of four recombinant human drugs for haemophilia. He is inventor or co-inventor of 36 patents, including the anti-tPA monoclonal antibody and Fab that form the basis of EmstoPA.
Clinical Advisors
Charles V. Pollack Jr
MA, MD, FACEP, FAAEM, FAHA, FESC, FCPP
Principal Clinician-Scientist, Department of Emergency Medicine, University of Mississippi, USA. Lead investigator and author on the landmark NEJM paper: Idarucizumab for Dabigatran Reversal.
Alexander (Andre) Cohen
MBBS, MSc, MD, FRACP, FESC
Department of Haematological Medicine, Guy’s and St Thomas’ NHS Trust, King’s College London. Vascular Physician. Author on the landmark NEJM paper: Andexanet Alfa for Acute Bleeding Associated with Factor Xa Inhibitors.